Nectin-4
Assets acting on this target.
- Class
- Nectin-4-directed drug conjugate (delivers a cytotoxic payload to Nectin-4-expressing cells)
- Pathway
- Cell-adhesion molecule overexpressed in urothelial, breast, lung, colorectal, and cervical cancers (~80-90% of urothelial cancers positive)
Nectin-4 is a cell-surface adhesion protein that helps epithelial cells stick to their neighbors and organize into tissue layers. In several cancers, particularly urothelial (bladder-lineage) cancer, tumor cells display markedly more Nectin-4 on their surface than normal tissue, making it a useful flag for identifying malignant cells even though the protein itself is not typically the driver of tumor growth. Because of this high, relatively selective surface expression, Nectin-4 has become a preferred docking point for "targeted delivery" therapies: rather than trying to block its normal adhesive function, these agents use an antibody, small molecule, or specialized miniprotein that binds Nectin-4 to guide a cytotoxic payload directly to the tumor cell. Approaches range from antibody-drug conjugates carrying chemotherapy-like payloads to radiopharmaceuticals that deliver localized radiation once bound and internalized. This strategy aims to concentrate cell-killing effects within Nectin-4-high tumor tissue while limiting exposure of tissues where the protein is absent or expressed at low levels. The broad relevance of this mechanism spans urothelial, breast, lung, colorectal, and cervical cancers, all of which can show substantial Nectin-4 overexpression, though urothelial cancer shows the highest and most consistent positivity.
Related mechanisms
Nectin-4 drugs compared
6 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| Enfortumab Vedotin | Astellas Pharma, Pfizer | antibody-drug conjugate | Approved | Approved in Bladder Cancer; Phase 1/2 in Non-Small Cell Lung Cancer |
| Notiretatug rezetecan | Jiangsu Hengrui Pharmaceuticals | antibody-drug conjugate | Phase 3 | Phase 3 in Cervical Cancer; Phase 3 in Urothelial Carcinoma; Phase 2 in HR+/HER2- Metastatic Breast Cancer; Phase 2 in Non-Small Cell Lung Cancer |
| Sutantatug envedotin | Corbus Pharmaceuticals, CSPC Megalith Biopharmaceutical | antibody-drug conjugate | Phase 3 | Phase 3 in Cervical Cancer; Phase 3 in Urothelial Carcinoma |
| Zelenectide pevedotin | BicycleTx Limited | peptide | Phase 2 | Phase 2 in Urothelial Carcinoma |
| IPH4502 | Innate Pharma | antibody-drug conjugate | Phase 1 | Not recorded |
| LY4052031 | Eli Lilly | antibody-drug conjugate | Phase 1 | Phase 1 in Non-Small Cell Lung Cancer; Phase 1 in Urothelial Carcinoma |